| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(99)01575-5 |
| P698 | PubMed publication ID | 10470708 |
| P2093 | author name string | J N Boletis | |
| H M Moutsopoulos | |||
| J P Ioannidis | |||
| K A Boki | |||
| P2860 | cites work | Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data | Q36748174 |
| Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs | Q68859513 | ||
| Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy | Q72849010 | ||
| P433 | issue | 9178 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lupus nephritis | Q1621830 |
| P304 | page(s) | 569-570 | |
| P577 | publication date | 1999-08-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis | |
| P478 | volume | 354 |
| Q34250896 | Clinical trials in lupus nephritis |
| Q36264883 | Clinical uses of intravenous immunoglobulin. |
| Q34988089 | Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge |
| Q33882751 | Current status of lupus nephritis |
| Q33385332 | Evidence for the use of intravenous immunoglobulins--a review of the literature |
| Q75258800 | Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases |
| Q93062532 | High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease |
| Q34516575 | Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins |
| Q57689077 | Immunosuppressive treatment for proliferative lupus nephritis |
| Q35102141 | Indications for IVIG in rheumatic diseases |
| Q35542385 | Intravenous immune globulins: an update for clinicians |
| Q34574581 | Intravenous immunoglobulin in neurological disease: a specialist review. |
| Q36302368 | Intravenous immunoglobulin in the management of lupus nephritis. |
| Q26851698 | Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis |
| Q33369794 | Intravenous immunoglobulin therapy and systemic lupus erythematosus |
| Q37873722 | Intravenous immunoglobulin therapy in rheumatic diseases |
| Q36602778 | Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders |
| Q36757383 | Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. |
| Q50231116 | Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology |
| Q35553102 | Lupus nephritis: current issues |
| Q22000837 | Lupus nephritis: current update |
| Q36807468 | Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. |
| Q34990105 | New therapies: plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies |
| Q35039863 | Newer drugs for the treatment of lupus nephritis |
| Q34439259 | Pregnancy and renal failure: the case for application of dosage guidelines |
| Q37026795 | Recent advances on pathogenesis and therapies in systemic sclerosis |
| Q73730202 | Systemic lupus erythematosus |
| Q46776600 | The efficiency of intraperitoneal high-dose immunoglobulin in experimental nephrotic syndrome |
| Q24202572 | Treatment for lupus nephritis |
| Q24247408 | Treatment for lupus nephritis |
| Q42728756 | Treatment of lupus nephritis |
| Q78814998 | Treatment of lupus nephritis |
| Q37822658 | Treatment of proliferative lupus nephritis: a slowly changing landscape |
| Q35201234 | Treatment of severe proliferative lupus nephritis: the current state |
| Q33342024 | Treatment options for juvenile-onset systemic lupus erythematosus |
Search more.